Ligand Pharmaceuticals Incorporated (LGND) Stock Analysis & AI Equity Report
Ligand Pharmaceuticals Incorporated (LGND) overview
Ligand Pharmaceuticals Incorporated (LGND) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 268m and operating profit of USD 41.0m; the year-end share price was 189.07 USD and market capitalisation was USD 3,739m. Ligand Pharmaceuticals Incorporated is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ligand Pharmaceuticals Incorporated's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals invests in and structures royalty interests in mid- to late-stage development and commercial biopharmaceutical products, partnering with biopharmaceutical companies on development and commercialization. It also operates Captisol and NITRICIL platform technologies. Its revenue comes primarily from partner product royalties, alongside Captisol material sales and license fees and milestone payments.
Generate the Ligand Pharmaceuticals Incorporated report
Ligand Pharmaceuticals Incorporated is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ligand Pharmaceuticals Incorporated and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Ligand Pharmaceuticals Incorporated
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.